Vimarsana
Biggest News Aggregation in the World

Page 31 - Lymph Nodes News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Lymph Nodes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Lymph Nodes Today - Breaking & Trending Today

Does Adding Pembro Improve PFS in High-Risk Cervical Cancer? - Vimarsana News

Does Adding Pembro Improve PFS in High-Risk Cervical Cancer?

Pembrolizumab improved progression-free survival when added to standard chemoradiotherapy in newly diagnosed, locally advanced cervical cancer, new data show.

FDA Approves Nivolumab for Resected Stage IIB/C Melanoma - Vimarsana News

FDA Approves Nivolumab for Resected Stage IIB/C Melanoma

The new approval expands the melanoma indication for nivolumab to earlier-stage disease.

Omitting SLN Biopsy Safe for Some Early Breast Cancers - Vimarsana News

Omitting SLN Biopsy Safe for Some Early Breast Cancers

Patients with early breast cancer and negative ultrasound axillary lymph node staging had similar locoregional relapse and distant DFS at 5 years whether or not they received SLN biopsy.

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients - Vimarsana News

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

Unlocking the secret soldiers: How dendritic cells could revolutionize cancer immunotherapy - Vimarsana News

Unlocking the secret soldiers: How dendritic cells could revolutionize cancer immunotherapy

A recent review in the journal Immunity delves into the crucial role of dendritic cells (DCs) in shaping T-cell responses in cancer, highlighting their importance in both priming anti-tumor immunity and in ongoing immune interactions within tumors. The findings underscore the potential of DCs as key targets for next-generation cancer immunotherapies.